The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...
The CGM market presents significant opportunities driven by rising diabetes prevalence and technological advancements. Key ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
Experts weigh in on the most promising AI applications, from diabetic retinopathy screening to smarter insulin delivery, and the barriers that remain to widespread adoption and access.
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
Aptiva Medical, a provider of continuous glucose monitoring (CGM) systems and a portfolio company of Greenleaf Ventures, has completed its acquisition of VeraMed Health.
Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense 365 ...
Please provide your email address to receive an email when new articles are posted on . The Tandem Mobi automated insulin delivery system can be integrated with ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback